NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-GM-22-012 from the NIH Guide for Grants and Contracts
Notice NOT-GM-22-011 from the NIH Guide for Grants and Contracts
Notice of Special Interest (NOSI): Administrative Supplements to Enhance Program Evaluation Capacity
Notice NOT-GM-22-013 from the NIH Guide for Grants and Contracts
Notice NOT-GM-22-014 from the NIH Guide for Grants and Contracts
Notice NOT-GM-22-015 from the NIH Guide for Grants and Contracts
Notice NOT-GM-22-028 from the NIH Guide for Grants and Contracts
Notice NOT-TR-22-014 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-22-002 from the NIH Guide for Grants and Contracts. This purpose of this RFA is to solicit applications for the Nonhuman Primate Transplantation Tolerance Cooperative Study Group (NHPCSG), a multi-center, cooperative program dedicated to developing, optimizing, and evaluating approaches to induce and maintain immune tolerance to allogeneic transplants in nonhuman primate (NHP) models. The over-arching goal is to facilitate clinical translation of safe and effective tolerance-induction protocols for long-term graft survival.
Notice NOT-AI-22-027 from the NIH Guide for Grants and Contracts
Notice NOT-AA-22-007 from the NIH Guide for Grants and Contracts
Notice NOT-AA-22-006 from the NIH Guide for Grants and Contracts
Notice NOT-AA-22-005 from the NIH Guide for Grants and Contracts
Notice NOT-AA-22-004 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-22-111 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) supports systematic and scalable approaches to profile the biological function of genes with an excess of damaging mutations in patients with neurodevelopmental and psychiatric disorders. Current understanding of the relationship between genetic and phenotypic variation is limited and one of the main bottlenecks in translating disease-associated genes to biology lies in the lack of scalable experimental platforms that can extend the unbiased nature of gene discovery to the discovery of biological mechanisms. This concept will attempt to fill that gap while also providing a bridge between existing NIMH efforts such as PsychENCODE and Convergent Neuroscience. New technologies and approaches are now making it possible to systematically implement high-throughput assays to determine how disease-linked genetic variation impacts neural function across biological levels of organization. This initiative proposes a series of FOAs to support the large-scale implementation of high-throughput assays to interrogate the molecular, cellular and physiological function of hundreds of disease-associated genes in parallel. A combination of full-scale and pilot projects will form a consortium for broad characterization of risk genes across an array of endpoints relevant to CNS function using a variety of experimental platforms (e.g., cellular, organismal). A consortium coordination center (CCC) will serve as a central hub providing administrative coordination across projects, including data and tools harmonization, development of an open-source portal to create a unified dataset and creating a standardized set of biological resources for use by the research community.
Funding Opportunity RFA-MH-22-110 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) supports systematic and scalable approaches to profile the biological function of genes with an excess of damaging mutations in patients with neurodevelopmental and psychiatric disorders. Current understanding of the relationship between genetic and phenotypic variation is limited and one of the main bottlenecks in translating disease-associated genes to biology lies in the lack of scalable experimental platforms that can extend the unbiased nature of gene discovery to the discovery of biological mechanisms. This concept will attempt to fill that gap while also providing a bridge between existing NIMH efforts such as PsychENCODE and Convergent Neuroscience. New technologies and approaches are now making it possible to systematically implement high-throughput assays to determine how disease-linked genetic variation impacts neural function across biological levels of organization. This initiative proposes a series of FOAs to support the large-scale implementation of high-throughput assays to interrogate the molecular, cellular and physiological function of hundreds of disease-associated genes in parallel. A combination of full-scale and pilot projects will form a consortium for broad characterization of risk genes across an array of endpoints relevant to CNS function using a variety of experimental platforms (e.g., cellular, organismal). A consortium coordination center (CCC) will serve as a central hub providing administrative coordination across projects, including data and tools harmonization, development of an open-source portal to create a unified dataset and creating a standardized set of biological resources for use by the research community.
Notice NOT-EY-22-003 from the NIH Guide for Grants and Contracts
Notice NOT-MH-22-140 from the NIH Guide for Grants and Contracts
Notice NOT-HL-22-007 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-054 from the NIH Guide for Grants and Contracts
Notice NOT-DA-22-008 from the NIH Guide for Grants and Contracts